Separate names with a comma.
I interviewed the CEOs of Reddit, Colgate-Palmolive, and 6 other top companies about leading for the long run. Here’s what they said...
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in...
Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants https://www.science.org/doi/10.1126/sciadv.aeb3034 This paper is...
Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003?...
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026...
GOP Senator To File Bill Promoting Psychedelics Research And Treatment For Veterans...
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst...
Ukraine's Other Battle: Healing the Invisible Wounds of War Ukraine's therapists seek ways to fund trials of psychedelics despite huge hurdles....
BPL-003 Nasal Spray Shows Quick and Enduring Effect in Treatment-Resistant Depression...
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of...
DT-402 will make $DFTX a 20B company long term after DT-120 is approved. If a treatment could improve social functioning or learning, it could...
ATAI Exploring $2B+ Deal for Psychedelic Depression Drug (Bloomberg Summary + Context) A new Bloomberg report says **Atai Life Sciences’ joint...
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression March 3, 2026 Aligned with FDA on...
$DFTX Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says Definium Therapeutics (NASDAQ:DFTX - Get Free...
Psychedelics Legalization Pipeline: 4 Psychedelic Drugs Seeking FDA Approval...
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates Share Emerge (Phase 3 MDD) enrollment complete; topline data...
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder February...
